CTOs on the Move

VistaPharm

www.vistapharm.com

 
VistaPharm is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vistapharm.com
  • 2224 Cahaba Valley Dr Ste b3
    Birmingham, AL USA 35242
  • Phone: 205.981.1387

Executives

Name Title Contact Details

Similar Companies

Humanigen

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralizati.

TriRx

Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.

Meitheal Pharmaceuticals

Founded in 2017, Meitheal Pharmaceuticals is a privately owned pharmaceutical company focusing on generic injectable products. Headquartered near Chicago, Illinois, Meitheal has an established management team and an aggressive growth strategy. Through global partnerships, our goal is to bring supply to US healthcare providers that demand a reliable, high quality, yet affordable supply of injectables.

Stratus Pharmaceuticals

Stratus Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InflaRx

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.